Tags

Type your tag names separated by a space and hit enter

Surveillance for travel-associated legionnaires disease--United States, 2005-2006.
MMWR Morb Mortal Wkly Rep. 2007 Dec 07; 56(48):1261-3.MM

Abstract

An estimated 8,000-18,000 persons are hospitalized with Legionnaires disease (LD) each year in the United States, and approximately 20% of reported LD cases are associated with travel. Outbreaks of travel-associated LD can be difficult to detect because travelers disperse and Legionella-specific diagnostic tests are underutilized. Consequently, clinicians and health departments often are unaware when more than one LD case is associated with a common travel destination. In 2005, the Council of State and Territorial Epidemiologists (CSTE) adopted a position statement recommending enhanced surveillance measures for LD, with emphasis on diagnosis and reporting of confirmed travel-associated LD cases within 7 days. The rationale for enhanced surveillance was that earlier detection might lead to more rapid identification of a source (e.g., cooling tower) and expedite prevention measures (e.g., cleaning and chlorination). To 1) assess data from 32 states that used a supplementary reporting system for LD, 2) describe the epidemiology of travel-associated LD, and 3) compare characteristics of travel-associated cases with those of cases not associated with travel, CDC analyzed LD cases reported via the supplementary system during 2005-2006. The results of that analysis indicated that the proportion of LD cases that were travel associated remained stable from 2005 (23%) to 2006 (25%), the proportion of travel-associated cases reported via a dedicated CDC e-mail address increased from 11% to 24%, and the number of reported clusters of travel-associated LD increased from two in 2005 to eight in 2006. These results suggest that, to fully assess the benefits of enhanced LD surveillance, more states will need to adopt the CSTE recommendations.

Authors

Centers for Disease Control and Prevention (CDC)
No affiliation info available

MeSH

AdultAgedAged, 80 and overFemaleHumansLegionnaires' DiseaseMaleMiddle AgedPopulation SurveillanceTravelUnited States

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18059257

Citation

Centers for Disease Control and Prevention (CDC). "Surveillance for Travel-associated Legionnaires disease--United States, 2005-2006." MMWR. Morbidity and Mortality Weekly Report, vol. 56, no. 48, 2007, pp. 1261-3.
Centers for Disease Control and Prevention (CDC). Surveillance for travel-associated legionnaires disease--United States, 2005-2006. MMWR Morb Mortal Wkly Rep. 2007;56(48):1261-3.
Centers for Disease Control and Prevention (CDC). (2007). Surveillance for travel-associated legionnaires disease--United States, 2005-2006. MMWR. Morbidity and Mortality Weekly Report, 56(48), 1261-3.
Centers for Disease Control and Prevention (CDC). Surveillance for Travel-associated Legionnaires disease--United States, 2005-2006. MMWR Morb Mortal Wkly Rep. 2007 Dec 7;56(48):1261-3. PubMed PMID: 18059257.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Surveillance for travel-associated legionnaires disease--United States, 2005-2006. A1 - ,, PY - 2007/12/7/pubmed PY - 2007/12/8/medline PY - 2007/12/7/entrez SP - 1261 EP - 3 JF - MMWR. Morbidity and mortality weekly report JO - MMWR Morb Mortal Wkly Rep VL - 56 IS - 48 N2 - An estimated 8,000-18,000 persons are hospitalized with Legionnaires disease (LD) each year in the United States, and approximately 20% of reported LD cases are associated with travel. Outbreaks of travel-associated LD can be difficult to detect because travelers disperse and Legionella-specific diagnostic tests are underutilized. Consequently, clinicians and health departments often are unaware when more than one LD case is associated with a common travel destination. In 2005, the Council of State and Territorial Epidemiologists (CSTE) adopted a position statement recommending enhanced surveillance measures for LD, with emphasis on diagnosis and reporting of confirmed travel-associated LD cases within 7 days. The rationale for enhanced surveillance was that earlier detection might lead to more rapid identification of a source (e.g., cooling tower) and expedite prevention measures (e.g., cleaning and chlorination). To 1) assess data from 32 states that used a supplementary reporting system for LD, 2) describe the epidemiology of travel-associated LD, and 3) compare characteristics of travel-associated cases with those of cases not associated with travel, CDC analyzed LD cases reported via the supplementary system during 2005-2006. The results of that analysis indicated that the proportion of LD cases that were travel associated remained stable from 2005 (23%) to 2006 (25%), the proportion of travel-associated cases reported via a dedicated CDC e-mail address increased from 11% to 24%, and the number of reported clusters of travel-associated LD increased from two in 2005 to eight in 2006. These results suggest that, to fully assess the benefits of enhanced LD surveillance, more states will need to adopt the CSTE recommendations. SN - 1545-861X UR - https://www.unboundmedicine.com/medline/citation/18059257/full_citation DB - PRIME DP - Unbound Medicine ER -